OBJECTIVE Because of the lack of head-to-head trials, the aim was to indirectly compare sodium glucose transporter-2 (SGLT-2) inhibitors in the treatment of type 2 diabetes. DESIGN Systematic review and network meta-analysis. DATA SOURCES MEDLINE and EMBASE were searched from January 2005 to January 2015. ELIGIBILITY CRITERIA Randomised controlled trials assessing the efficacy of SGLT-2 i...

Aim . To evaluate the cost-effectiveness of achieving target indicator "Reduction cardiovascular mortality population" State Program "Health Development" when using drugs valsartan+sacubitril, dapagliflozin and empagliflozin in patients with New York Heart Association (NYHA) class II-IV heart failure reduced ejection fraction ≤40% s 2023-2024. Material methods The population was Russian who rec...

As the number of bariatric surgeries in United States plateaus at nearly 200,000, prevalence post-bariatric hypoglycemia (PBH) is escalating. Since pathophysiology driving PBH not fully understood, treatment for can be challenging clinical practice. Most recently, use GLP1-RA or SGLT2i have been reported as monotherapy options PBH. We are presenting case a patient without diabetes who failed co...

Abstract Background and Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2i) some glucagon-like-1 receptor agonists (GLP1-RA) have demonstrated to delay diabetic nephropathy (DN) progression. Potentially, the combination of these two therapeutic approaches on top standard care with renin angiotensin system (RAS) blockers could exert additive cardiorenal protection in milieu. The present stud...

Abstract Type II Diabetes mellitus (T2DM) leads via hyperglycemia (HG)-associated inflammation and oxidative stress to vascular cell dysfunction. The EMPA-REG trial revealed a reduction of cardiovascular mortality in T2DM patients by Empagliflozin, sodium-glucose co-transporter-2 (SGLT-2) inhibitor. SGLT-2 is expressed on monocytes endothelial cells (EC), therefore the aim this study was invest...

MODY-5 is a rare autosomal dominant form of monogenic diabetes attributed to deletions chromosome 17q12 with impaired expression HNF1β (Hepatocyte Nuclear Factor 1 homeobox Beta. The deficient HNF1B down regulated the FXYD2. Refractory hypomagnesemia commonly observed in patients due downregulated FXYD2 which blocked encoding γ (gamma) subunit Na+-K+-ATPase and indirectly led hypomagnesemia. SG...

Background: Empagliflozin reduces the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular disease. We sought to elucidate effect empagliflozin as an add-on therapy on decongestion renal function admitted acute decompensated failure. Methods: The study was terminated early due COVID-19 pandemic. enrolled 59 consecutive Patients were randomly assigned rec...

Objective: The purpose of the present study is to develop simple, fast, accurate, precise, and robust stability-indicating reverse phase high-performance liquid chromatographic (RP-HPLC) method for simultaneous determination metformin HCl, empagliflozin, linagliptin in their combinations. Methods: Separation was performed on Agilent Eclipse XDB-C18 (250 mm x 4.6 mm, 5 µm) column with a mobile c...

BACKGROUND Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of pharmacologic agents developed for the treatment of type 2 diabetes mellitus (T2DM). Their unique mechanism of action is independent of pancreatic beta-cell function or the degree of insulin resistance, giving these agents the potential for use in combination with any of the existing classes of glucose-lowering age...

Background. Cardiovascular morbidity increases notably among patients with diabetes. A correlation between leptin resistance and cardiovascular risk was found in arterial hypertension metabolic syndrome. However, there are no data about the influence of empagliflozin on level; effectiveness against key factors diabetic normal weight overweight has not been studied yet. The purpose this work to ...